Welcome to our dedicated page for Ocuphire Pharma SEC filings (Ticker: OCUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OCUP SEC filings page on Stock Titan provides access to the historical regulatory record for Ocuphire Pharma, Inc., which later combined with Opus Genetics, Inc. and was renamed Opus Genetics. After the transaction, SEC reports identify the registrant as Opus Genetics, Inc., but they remain part of the continuous filing history linked to the former Nasdaq ticker OCUP and the current ticker "IRD."
Through this archive, readers can review current and historical reports that describe the company’s evolution from a clinical-stage ophthalmic biopharmaceutical developer of small-molecule therapies to a combined entity with a pipeline that includes adeno-associated virus-based gene therapies for inherited retinal diseases. Filings such as Forms 8-K detail material events including funding agreements for specific gene therapy programs, changes in executive leadership, private placements of common stock, and collaboration arrangements with organizations like the Foundation Fighting Blindness Retinal Degeneration Fund and other funding parties.
Investors interested in the development of APX3330 for non-proliferative diabetic retinopathy and Phentolamine Ophthalmic Solution 0.75% for presbyopia, dim light disturbances, and pharmacologically induced mydriasis can use the filings to trace clinical and regulatory milestones, license terms with commercial partners, and disclosures about expected cash runway. As the company transitioned to Opus Genetics, additional filings describe its focus on gene therapies for conditions such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa.
On Stock Titan, these SEC documents are updated from EDGAR and can be paired with AI-powered summaries that explain key points in plain language. Users can quickly scan 8-Ks for material agreements, capital raises, and leadership changes, and follow how historical OCUP programs and obligations carry forward into the Opus Genetics era under the IRD ticker.
Opus Genetics, Inc. Schedule 13G disclosures show that a group of affiliated Bios entities and related parties report shared beneficial ownership of 3,683,429 shares, representing 6.2% of the common stock (based on 59,661,197 shares outstanding as of May 12, 2025). The holdings are reported as shared voting and dispositive power; individual Bios Fund III vehicles report smaller direct stakes (for example, Bios Fund III QP, LP reports 2,801,953 shares or 4.7%). The filing identifies the security as Common Stock, par $0.0001, CUSIP 00887A204.
The Schedule includes standard confirmations of passive intent: the filers certify the securities were not acquired to change or influence issuer control. Contact and organizational details are provided for the issuer (principal office in Durham, NC) and the filers (principal office in Fort Worth, TX), and related organizational relationships among the Bios and Cavu entities are disclosed to explain shared power.
Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.
The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.